Blog
RSS FeedPosted by Michael Wonder on 24 Jul 2018
Prescribing biosimilars
24 July 2018 - Slow adoption is costly. ...
Posted by Michael Wonder on 04 Jul 2018
PBAC to adopt a revised approach to considering brand equivalence/substitution for biosimilar medicines
4 July 2018 - PBAC to consult with Medicines Australia on the possible withdrawal of the TGA-PBAC parallel process for ...
Posted by Michael Wonder on 02 Jul 2018
Is nudging biologic patients towards biosimilars a good choice for plan sponsors?
29 June 2018 - A recent study examining the potential savings determined that, based on the uptake of available biosimilars ...
Posted by Michael Wonder on 30 Apr 2018
A new incentive to encourage the prescription of biosimilars
26 April 2018 - The Directorate General of Health Care Supply and the Directorate General of Social Security published a ...
Posted by Michael Wonder on 23 Apr 2018
Biosimilar education grant
23 April 2018 - A grant has been awarded to GBMA Education Limited to complement and extend the activities undertaken by ...
Posted by Michael Wonder on 19 Apr 2018
Four Canadian provinces add Erelzi (etanercept) to provincial drug plans for the treatment of multiple inflammatory diseases
19 April 2018 - Erelzi has been added to drug formularies in Manitoba, Saskatchewan, Alberta and Newfoundland based on specific criteria ...
Posted by Michael Wonder on 06 Feb 2018
Quebec adds Erelzi (etanercept) to provincial drug plans for the treatment of multiple inflammatory diseases
5 February 2018 - Erelzi has been added to the Quebec Drug Insurance Plan based on specific criteria for the treatment ...
Posted by Michael Wonder on 10 Jan 2018
Ontario has added Erelzi (etanercept) to public drug plan for the treatment of multiple inflammatory diseases
9 January 2018 - Erelzi has been added to public drug plan based on specific criteria in Ontario for the treatment ...
Posted by Michael Wonder on 20 Dec 2017
Agenda for the March 2018 PBAC meeting
20 December 2017 - The agenda for the March 2018 PBAC meeting is now available. ...
Posted by Michael Wonder on 13 Dec 2017
Update on revised process for biosimilars
12 December 2017 - In August 2017, CADTH invited stakeholder comments and feedback on a proposal to revise the submission and ...
Posted by Michael Wonder on 02 Dec 2017
Public Summary Documents - August 2017 PBAC meeting
1 December 2017 - The public summary document for etanercept from the August 2017 PBAC meeting is now available. ...
Posted by Michael Wonder on 30 Nov 2017
Which biosimilar medicines are available in Australia?
30 November 2017 - Information is available on the Department of Health website setting out the biosimilar brands of medicines which ...
Posted by Michael Wonder on 16 Nov 2017
British Columbia and Prince Edward Island become the first provinces to add Erelzi (etanercept) to public drug plans for the treatment of multiple inflammatory diseases
16 November 2017 - Erelzi also becomes the first biosimilar indicated for polyarticular juvenile idiopathic arthritis under these provincial public drug ...
Posted by Michael Wonder on 24 Oct 2017
AMA submission - Government proposals to increase biosimilar prescribing
19 October 2017 - The Australian Medical Association encourages medical practitioners to offer generic medicine choices when it is safe and ...
Posted by Michael Wonder on 22 Sep 2017
New fact sheets - infliximab biosimilars
22 September 2017 - Fact sheets about infliximab biosimilars for consumers and health care professionals are now available on the Department ...